About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Financial | NANOBIOTIX’ Management statement on recent share price variation
Financial | NANOBIOTIX revenue for the 1st quarter of 2018
15 May 2018
Scientific Clinical | Nanobiotix announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3
21 June 2018
Financial | NANOBIOTIX’ Management statement on recent share price variation
Published by
adminvl
on
6 June 2018
No translations available for this page
